Jupiter Orphan Therapeutics
601 Heritage Drive
Suite 137
Jupiter
Florida
33458
United States
Tel: 561-308-7780
Website: http://www.jupiterorphan.com/
Email: info@jupiterorphan.com
About Jupiter Orphan Therapeutics
Jupiter Orphan Therapeutics (JOT) is a specialty pharmaceutical company developing therapies for rare diseases linked to single gene deficiencies. JOT, a Delaware Corporation with it's principal office located in Jupiter, FL, USA, was founded in the summer of 2015. In its short period of operations, JOT has assembled a very strong management and scientific team as well as defined five pipeline products which of one is already in Phase II.YEAR FOUNDED:
2015
LEADERSHIP:
Founder and CEO: Christer Rosén
CFO: Jacob Uittenbogaard
Co-Founder and CMO: Dr. Claes Wahlestedt, MD, Ph.D.
CSO: Marshall Hayward
VP of Science Research: Shaun P Brothers, Ph.D. ?? PIPELINE:
Please click here for Jupiter Orphan Therapeutics' pipeline.
18 articles about Jupiter Orphan Therapeutics
-
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
9/14/2021
Jupiter Orphan Therapeutics, Inc., a clinical stage pharmaceutical company focused on treating central nervous system (CNS) disorders and rare diseases, today announced a name change to Jupiter Neurosciences, Inc., and a new website, www.jupiterneurosciences.com.
-
Jupiter Orphan Therapeutics Announces First Patient Dosed in Phase I Dose Escalation Study of JOTROL™
1/11/2021
Jupiter Orphan Therapeutics, Inc. ("JOT") a biotechnology company pioneering a novel and disease modifying product named JOTROL™, today announced that the first patient has been dosed in a Phase I dose escalation study of JOTROL™
-
Jupiter Orphan Therapeutics Announces U.S. Patent for Its Resveratrol Formulation
10/1/2020
Jupiter Orphan Therapeutics, Inc. announced that its flagship JOTROLTM resveratrol delivery system has been granted patent No. 10780056 by the U.S. Patent & Trademark Office, in addition to its European patents, issued earlier this year.
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
Jupiter Orphan Announces Federal Grant to ADVANCE JOTROL™ to Phase I Clinical Trial for Alzheimer's
9/22/2020
Jupiter Orphan Therapeutics, Inc., a clinical-stage drug platform company focused on neurological and rare diseases, announced today that the National Institute on Aging at the NIH will award it $1.76 million (over 1 year) to support a Phase I clinical study of JOTROL™, for the treatment of early-stage Alzheimer's disease.
-
BioSpace Movers & Shakers, May 8
5/8/2020
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Jupiter Orphan Therapeutics, Inc. Strengthens its Advisory Positions
5/5/2020
Jupiter Orphan Therapeutics, Inc. announced that it is strengthening its Scientific Advisory Board with the addition of Dr. Charbel Moussa, and created a new advisory position in patient advocacy by the appointment of Mark Dant..
-
Professor Rudolph E. Tanzi, Ph.D., World Renowned Alzheimer's Researcher, Joins Jupiter Orphan Therapeutics
11/18/2019
Dr. Tanzi stated "I am excited about being able to work with JOT to bring drugs to patients who need solutions for neurological diseases."
-
Jupiter Orphan Therapeutics, Inc. Selected to Participate at Upcoming Cavendish BioHealth Impact Forum
6/13/2019
Forum uniquely brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and the life sciences
-
Jupiter Orphan Therapeutics Announces Favorable Data Which Expands JOTROL's Applications to the Estimated $5 Billion Mitochondrial Rare Disease Market
8/22/2018
New data regarding an increase in mitochondrial biogenesis in liver and brain from a recently performed study in a frequently studied Alzheimer's disease animal model, the triple transgenic mouse.
-
Jupiter Orphan Therapeutics, Inc. Adds Professor Gino Cortopassi, Ph.D. to Assist in The Company's Mitochondrial Disease Projects
3/19/2018
Jupiter Orphan Therapeutics, Inc. (JOT) today announced that the well-known scientist Gino Cortopassi, Ph.D. joined JOT as a member of its Scientific Advisory Board (SAB).
-
Jupiter Orphan Therapeutics Announces Submission of Investigational New Drug Application (IND) For Treatment Of Mucopolysaccharidosis Type-I
3/14/2018
Jupiter Orphan Therapeutics, Inc. ("JOT"), Jupiter, FL, today announced that it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis Type-I (MPSI).
-
Jupiter Orphan Therapeutics in Process to Submit IND for MPSI and Other Indications
2/5/2018
This will be the first of several anticipated IND submissions in 2018 utilizing JOT's platform product, JOTROL.
-
Jupiter Orphan Therapeutics Receives Orphan Drug Designation For Its Trans-Resveratrol Product JOTROL For Treatment Of Friedreich's Ataxia
8/22/2017
-
Jupiter Orphan Therapeutics Partners With InSymbiosis
4/25/2017
-
Catalent To Develop Softgel Capsules For Jupiter Orphan Therapeutics’s Leading Orphan Disease Candidates
1/9/2017
-
Jupiter Orphan Therapeutics Secures Financing And Adds Board Member
1/5/2017
-
Jupiter Orphan Therapeutics Is Joined By Peter Elliott, Ph.D. And Ian Baker-Finch
11/1/2016